A study by co-author John Nolan, PhD, of the Macular Pigment Research Group at Waterford Institute of Technology and presented at the 18th International Symposium on Carotenoids in Lucerne, Switzerland, showed that the addition of (RS) meso-zeaxanthin, a non-dietary carotenoid found in many eye health supplements, contributes no additional efficacy for eye health in people with non-advanced age-related macular degeneration (early AMD).  The findings from the Central Retinal Enrichment Supplementation Trials (CREST) add doubt to the need for supplement formulations containing (RS) meso-zeaxanthin.

The CREST study examined the effect of adding (RS) meso-zeaxanthin to the standard National Eye Institute’s Age-Related Eye Disease Study 2 (AREDS2) formula of 10 mg lutein and 2 mg zeaxanthin, plus low zinc. The study participants were randomly assigned to one of two AREDS2 (with low zinc) treatment groups: with 10 mg (RS) meso-zeaxanthin or no (RS) meso-zeaxanthin. After 24 months of follow-up in 98 participants with early AMD, there were no significant differences in measures of macular pigment or visual function between the treatments.¹

“Supplement manufacturers should be aware that all ‘zeaxanthin’ is not the same. Some products are misrepresented as containing natural and dietary ‘zeaxanthin’ but contain a non-dietary, synthetic, zeaxanthin stereoisomer—3R, 3’S- zeaxanthin, or (RS) meso-zeaxanthin, which is one of three ‘zeaxanthin’ stereoisomers,” said Richard Roberts, PhD, Kemin Principal Manager, Technical Services. “The findings are important because they build on the available evidence that suggests there is no additional benefit of adding (RS) meso-zeaxanthin to eye health supplements.”

(RS) Meso-zeaxanthin contained in dietary supplements is synthetically made from lutein using high heat and a strong alkaline environment.² Research also indicates that (RS) meso-zeaxanthin present in the macula is made from dietary lutein and that supplemental (RS) meso-zeaxanthin may actually compete with lutein and zeaxanthin for absorption, keeping these important antioxidants from reaching the macula in the amounts needed for eye health.^3,4,5

“Eye health supplement formulators should ask if all ingredients used in their product formulations are supported by science for safety and effectiveness,” said Ceci Snyder, Global Vision Product Manager. FloraGLO^® Lutein, which contains the same dietary forms of lutein and zeaxanthin as found in common foods such as spinach, kale and broccoli, is a quality lutein backed by science. FloraGLO is supported by over 80 human clinical trial publications and is the number one recommended lutein brand by eye doctors.^6,7

The current study findings resulted from a European Research Council grant for the Central Retinal Enrichment Supplementation Trials (CREST). The research was conducted at the Macular Pigment Research Group, which is part of the Nutrition Research Centre Ireland at the School of Health Science, Waterford Institute of Technology in Waterford, Ireland. Study participants were diagnosed with early AMD. The findings continue to support the National Eye Institute’s AREDS2 formulation with 10 mg of FloraGLO Lutein and 2 mg zeaxanthin as the standard eye health supplement formulation for age-related eye conditions.

Nearly a half-century ago, KOHJIN Life Sciences began its pioneering research into the benefits of L-glutathione (GSH) in maintaining cell longevity, helping the body fight toxins, supporting liver function, and improving and beautifying skin.

Concurrent with this research, KOHJIN developed a proprietary method for producing the purest and most consistent glutathione product available, and was soon rewarded by becoming the world’s leading supplier of GSH in 1968, a position it still holds. Today, OPITAC™ Glutathione stands as the pinnacle of KOHJIN’s efforts, and remains the most trusted name in glutathione across the planet.

But this position isn’t symbolic, and trust isn’t simply bestowed, it’s earned. KOHJIN’s celebrated GSH has long enjoyed U.S. FDA-Notified Full GRAS status, as well as holding Kosher and Halal certifications. Its GMP-approved factories are industry models, and OPITAC™ was the first glutathione to achieve JP and USP monograph designation.

Now the company is pleased to announce yet another affirmation of the ongoing, unparalleled quality of OPITAC™ Glutathione, as it becomes the only glutathione product to be given a place of prominence as an OK Kosher Certification Featured Brand [ http://tinyurl.com/lrmxo4t ]. OK Kosher is among the oldest and most firmly-established Kosher certification agencies in existence. Its bold, circled “K” symbol is a revered signature of brands held to be of undisputed purity and unwavering quality.

There are many groups that can attest to a product’s being Kosher, but OK Kosher stands apart for the scope and rigor of its concerns and considerations. The organization doesn’t just certify that a product conforms to minimum Kashruth standards, it sets all new standards for the product’s fitness to meet the challenges of a more health conscious, environmentally conscious, and socially conscious world.

Being an OK Kosher Featured Brand isn’t an honor KOHJIN takes lightly, nor is it granted hastily. Every year, representatives of the organization visit KOHJIN Life Sciences laboratories to carefully assess the current status of the products being developed and released, as well as the overall integrity of the process, its efficiency, and its safety. Over time, this most respected of certification bodies made the determination to confer its authoritative mark of approval on the company, and in particular, its flagship pharmaceutical ingredient, OPITAC™ Glutathione.

Glutathione has gained recognition as a premier food ingredient of the new century. It detoxifies the body, activates liver function, counters cellular oxidation, removes free radicals from the bloodstream, beautifies the skin, and helps relieve muscle fatigue. When it was clinically proven that GHS, in the form of OPITAC™ Glutathione, could add to the body’s natural store of this important substance through oral supplementation, KOHJIN became even more cognizant of its responsibility to bring these benefits to all consumers, everywhere.

This recognition by OK Kosher, among the most trusted food certification institutes in the world, is a validation of KOHJIN’s untiring, half-century effort to maintain excellence at every level of its operation, and further assurance that OPITAC™ Glutathione is deserving of its leading role in the drive for more conscientious and health-aware lifestyles.

Omyapharm® 500-OG is a fine powder consisting of calcium carbonate and tribasic calcium phosphate. It is suitable for wet and dry granulation as well as for hot-melt extrusion. Omyapharm® 500-DG OG, meanwhile, is the granulated form of Omyapharm® 500-OG and contains a superdisintegrant. Thanks to its special granulation, Omyapharm® 500-DG OG offers improved flowability and can be directly compressed into tablets.

Omyapharm® 500-DG OG has special importance when it comes to orally dispersible tablets (ODTs) and granules (ODGs). Its high porosity and specific surface properties enable fast disintegration and excellent compactibility that results in harder tablets at low compression forces. Tablets formulated with the functionalized calcium carbonate can be filled in conventional packaging because of their mechanical strength, thus reducing costs and difficulties during the conditioning process. ODTs manufactured from this excipient disintegrate in less than ten seconds. At Omya’s booth, CPhI visitors will be able to see flavored ODT samples and experience their fast disintegration properties first hand.

Omya will also showcase its natural calcium carbonates Omyapure® and Omya-Cal®. Natural calcium carbonate is a high purity calcium source with 40 percent bioavailable calcium. This makes it a valuable ingredient for calcium supplementation – for instance, to treat conditions such as osteoporosis – and for antacid formulations to neutralize stomach acid.

Thanks to their comprehensive formulation know-how, the company’s experts are able to develop tailor-made formulations in response to specific customer needs.

An exciting new peer reviewed publication based on ongoing research on macular carotenoids from the University of Georgia demonstrates that supplementation with lutein and zeaxanthin isomers can protect against a growing issue among the general population – the undesirable effects of prolonged exposure to high-energy blue light emitted from digital screens of computers, tablets and smartphones.

Lutein and zeaxanthin isomers—known as the macular carotenoids—are natural filters of high-energy blue light. High-energy blue light reaches deep into the eye and can harm the macula – the region of the eye responsible for highest visual acuity– by promoting the production of free radicals. Short-term effects can cause eye fatigue while long-term exposure can lead to a progressive loss of visual function.

The B.L.U.E. study (an acronym for Blue Light User Exposure) was the subject of a recent paper, “Effects of macular carotenoid supplementation on visual performance, sleep quality, and adverse physical symptoms in those with high screen time exposure,” published in Foods 2017 (Stringham, et al.). This is the first study to examine the impact of macular carotenoids supplementation to protect visual health and performance, improve sleep quality and reduce eye strain and fatigue during prolonged exposure to blue light emitting digital screens.

“The effects of blue light on vision isn’t new.  However, 10 years ago we saw a surge in near field technology holding or using devices within arm’s length, resulting in increased complaints around high screen use – neck pain, eye strain and fatigue, headaches.” Stated Dr. James Stringham, the lead author of the paper. “This has led to an opportunity with supplementation – a simple mode of therapy with specific nutrients that have a wealth of benefits as they deposit in the eye.  After six months of supplementation we saw significant reduction around 30% in these symptoms and significant improvement in measures of visual performance and protection.”

The B.L.U.E. study was a 6-month randomized, double-blind, placebo-controlled supplementation trial with 48 healthy, young adults with screen time exposure of at least 6 hours daily. Subjects were evaluated at baseline, 3-months and 6-months for MPOD (Macular Pigment Optical Density) and markers of visual performance including contrast sensitivity, photostress recovery and disability glare. Sleep quality, which is affected by blue light exposure, and physical indicators of excessive screen use were also measured. The results show that supplementing with Lutemax 2020 significantly improved macular pigment optical density, visual performance and indicators of excessive screen use, including eye strain and fatigue and headache frequency. Sleep quality also improved significantly.

“At home, work and school your eyes are focused on digital devices for long periods of time. In many cases we spend more time staring into digital screens than sleeping.” said Abhijit Bhattacharya, President, OmniActive Health Technologies Ltd. “Even Children, whose eyes are more susceptible to the harmful effects of blue light, spend almost half their day staring into screens. This study is groundbreaking – the first of its kind.  And builds on an impressive body of evidence on Lutemax 2020 and its impact on vision and brain health.  The BLUE study has huge implications because it addresses the growing concern of prolonged ‘screen time’ that is happening across all age groups and offers a simple solution to protect the eyes in this digital age.”

Naturally-sourced zeaxanthin from Kemin Industries has been approved as a New Food Material by the National Health and Family Planning Commission (NHFPC) of China. The announcement offers manufacturers an exciting new opportunity to include natural zeaxanthin in supplements and foods for eye health benefits.

Dietary zeaxanthin and lutein are the carotenoids found in common foods and deposited in our eyes for vision health, with zeaxanthin more prevalent in the central region of the retina. Kemin ZeaONE^® Zeaxanthin (distributed by DSM as OPTISHARP^® Natural Zeaxanthin) is a naturally-sourced zeaxanthin from the same company that produces FloraGLO^® Lutein, the most studied lutein brand worldwide and the number one lutein recommended by doctors in the U.S.^1,2 ZeaONE Zeaxanthin provides the zeaxanthin form found in our diet, and is extracted from the petals of marigold flowers.

“We are excited to supply high-quality, naturally sourced zeaxanthin to Chinese companies looking for trusted ingredients that will help protect the eye health of Chinese consumers,” said Anita Norian, President of Kemin Human Nutrition and Health.
​
Chinese consumers can now benefit from the gold-standard eye health formulation of the Age-Related Eye Disease Study 2 (AREDS2), a study in more than 4,000 adults which showed that 2 mg of zeaxanthin along with 10 mg of FloraGLO Lutein reduced the risk of progression to advanced age-related macular degeneration (AMD).³

Zeaxanthin and lutein act as powerful antioxidants in the eye with clinically proven benefits for visual performance and function, in addition to age-related eye conditions such as AMD and cataracts.^4,5,6 Studies have also shown that zeaxanthin and lutein protect eyes from exposure to blue light, part of visible light and the most harmful to our eyes.^7,8

The approved zeaxanthin is listed under its scientific name in Chinese, (3R,3’R)-dihydroxy-β-carotene, and up to 4 mg per day can be included in product formulations.

• The MOSAIC clinical essay shows that chondroitin sulfate CS b-Bioactive® is superior to the anti-inflammatory drug celecoxib for delaying the disease’s progression
• It also reveals that chondroitin sulfate CS b-Bioactive® possesses the same level of efficiency as celecoxib for the improvement of pain and mobility in knee osteoarthritis, with the added advantage of a higher safety profile

Chondroitin sulfate CS b-Bioactive® (made by Bioiberica) delays osteoarthritis progression and is as effective as the anti-inflamatory drug celecoxib for improving the disease’s symptoms. These are the main conclusions of a new published[1] clinical essay presented by Professor Jean Pierre Pelletier[2] at the recent celebrated Annual European Congress of Rheumatology; being held in Madrid, Spain.

The MOSAIC clinical essay (24 MOnth study on Structural changes in knee osteoarthritis Assessed by mrI with Chondroitin sulfate) is a multicenter, randomized, double blind, controlled and comparative study, conducted by Bioiberica, carried out in five medical centers in Quebec (Canada). 194 patients suffering from knee osteoarthritis with inflammation (synovitis) and moderate pain were recruited to assess the effects of chondroitin sulfate (1.200 mg/ day) and celecoxib (200 mg/ day) over the loss of cartilage volume in knee osteoarthritis after 24 months.

The participants underwent three Quantitative Magnetic Resonance scans: one at the beginning of the study, a second one after one year and a third one at the end of the study. The results revealed that the progression of knee osteoarthritis is slower in patients receiving chondroitin sulfate CS b-Bioactive®. More precisely, this group experienced a statistically significant lower loss of cartilage volume as soon as after the first year of treatment, in comparison with those patients who received the anti inflammatory drug. Patients treated with chondroitin sulfate had a decrease in synovitis which was associated with a statistical significant decrease in cartilage loss.

In addition to that, a published[3] post hoc analysis of this clinical trial concludes that chondroitin sulfate has also a protective effect on the subchondral bone, reducing the knee bone curvature and therefore the disease’s progression.

“This data proves that chondroitin sulfate may delay the advance of osteoarthritis in the long term, and that it had a disease-modifying effect”, affirmed Professor Pelletier.

The MOSAIC study also evaluated the effects of both products on the disease’s symptoms. More precisely, the study evaluated their effects on pain, function, stiffness, joint efflux and swelling; concluding that both treatments were equally efficient across the entire study, reaching a clinically relevant symptom improvement of around 50%.

“The study confirms that both products are efficient for the treatment of osteoarthritis symptoms, although only chondroitin sulfate has the additional advantage of exerting a joint protection effect and a better safety profile”, concluded Professor Pelletier.

[1] Pelletier J-P, et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Research and Therapy 2016 Nov 3;18 (1):256.

[2] MD; professor of medicine, University of Montreal; director, Rheumatic Disease Unit, Department of Medicine, University of Montreal School of Medicine; head, Arthritis Division, University of Montreal Hospital Centre (CHUM); head, Chair in Osteoarthritis of the University of Montreal; and director, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM).

[3] Raynauld JP, et al. Bone curvature changes can predict the impact of treatment on cartilage volume loss in knee osteoarthritis: data from a 2-year clinical trial. Rheumatology 2017 Jun 1;56(6):989-998.

Gnosis has published a new “News from Science” issue focusing on Quatrefolic® the “innovActive” folate and the MTHFR polymorphism in pregnancy, this way continuing its dedication to education and awareness on the world of folate.

Folate status in pregnancy is a critical factor in proper fetal development. Since humans cannot synthesize folate and pregnant women do not consume adequate quantities of it through their diet, folate supplementation is required to prevent NTDs (neural tube defects) and established by several Health Authorities (i.e. FDA, EFSA).

Folic acid is not biologically active and needs to be converted into the metabolically active 5-methyltetrahydrofolate (5-MTHF) through a multi-steps process where the enzyme methylenetetrahydrofolate reductase (MTHFR) owns a key role. Some individuals, due to their unique genetic patterns and expression, have polymorphic forms of this enzyme and do not produce adequate or effective MTHFR.

Quatrefolic® is structurally analogous to the reduced and active form of folate so it completely bypasses the “damaged” MTHFR conversion step and delivers a “finished” folate the body can immediately use without any kind of metabolization.

Download available at http://www.quatrefolic.com/news_Folate_&_Pregnancy_the_new_issue_on_implications_of_MTHFR_polymorphism.php

If variety is the spice of life, Weider® is taking the saying to crazy heights. The sport and specialty nutrition company launched three new workout products in Europe that should meet the demands of fitness and exercise lovers. Each is anchored by Sustamine® L-Alanyl-L-Glutamine.

Two of the products are ready-to-drink supplements. Weider® BCAA RTD contains a blend of vitamins, niacin, B6 and Sustamine® that boosts energy, reduces fatigue and supports a healthy immune system.* Each lemon-lime flavoured, 250 ml can contains 3g of branch chained amino acids—leucine, isoleucine and valine—that impact muscle growth.*

For better hydration and endurance, Weider® Rush RTD packs 10 active ingredients, including 200mg of Sustamine®, that combine to increase muscle development, improve focus and boost liquid absorption during and after physical activity.* The 250ml, orange-flavoured drink is designed for all types of athletes—from daily exercisers to amateurs and professionals.*

If workout powders are more your speed, Weider® Total Rush 2.0 Fusion Force Pre-Workout Powder delivers the science that serves your muscles.* The newly redesigned Total Rush 2.0 gives you that final nudge to complete a workout and avoid energy slumps common after training.* Like its ready-to-drink siblings, Total Rush 2.0 contains 200mg of Sustamine® to increase muscular glutamine levels and improve hydration.* It comes in four flavours: raspberry, orange, cola and lime-lemon.

Muscles must be hydrated and engorged with glycogen. And when it’s all over, the body needs to recover. Sustamine® – a form of glutamine, the most abundant single amino acid in the body – provides essential support during times when the body undergoes large amounts of stress – like during intense weightlifting or dealing with the challenges of everyday life. On top of these benefits, research suggests that Sustamine® is absorbed more than 200 percent better than standard L-glutamine. This means you get better results while having to use less.*

“Since 1936, Weider® has developed dietary and workout supplements that give our customers the results they demand,” said Weider’s spokesperson. “It’s why we leveled up Total Rush 2.0 and introduced BCAA RTD and Rush RTD as part of our continuing commitment to improving exercise and workouts with products backed by proven clinical research like that done for Sustamine®.”

For information on these new Weider® products, visit https://www.weiderworld.com/products/new-products.

About Weider

Weider is a company which specializes in the manufacture and distribution of sports nutrition and health supplements. Established in 1936, Weider, with its founder Joe Weider at the fore, has promoted the education of people world-wide about all aspects of bodybuilding, fitness, health, well-being and an active lifestyle. Weider has earned the trust of people concerned about their health for one simple reason: for over half a century we have put the quality and effectiveness of our products before everything. For more information, visit www.weiderworld.com.

About Sustamine

Sustamine® L-Alanyl-L-Glutamine is a stable dipeptide of L-Alanine and L-Glutamine manufactured by Kyowa Hakko Bio Co., Ltd. Sustamine is more easily absorbed by the body than complex protein molecules. This makes Sustamine a highly effective ingredient for hydration, endurance and recovery.* Vegetarian, allergen-free and the only GRAS and Novel Food L-Alanyl-L-Glutamine, Sustamine is also tasteless, odorless, and stable in liquids.

Sustamine is an ingredient that works on multiple levels to help rehydrate the body and sustain energy levels during exertion. Sustamine combines L-Glutamine (the most important amino acid for stimulating muscle protein synthesis) and L-Alanine (an amino acid needed for rebuilding your body’s glycogen stores).

JUNE 2017 – Researchers at Central Michigan University have taken a closer look at Longvida® Optimized Curcumin. Previously, these researchers conducted amyloid binding work in vitro with promising results¹. Recently published, in the International Journal of Alzheimer’s Disease, Maiti P et al have compared standard, unformulated curcumin more closely to Longvida with SLCP™ Technology.

The present study, “was designed to compare the neuroprotective effects of [unformulated 95% curcumin equivalent to 80% free curcumin] and/or SLCP™ [Longvida® with 20% free curcumin], in vitro after exposure to Aβ42.”

It is important to note that the accumulation of amyloid beta (Aβ) proteins and phosphorlayted tau (p-tau) are key pathological hallmarks of AD². The researchers go on to explain that, the maintenance of cell survival protein markers, as well as decreasing oxidative stress, are vital factors in the delay of neurodegeneration or neuronal loss². In this study, Maiti and team brought a fresh perspective to the question: how does Longvida’s free curcumin compare to unformulated free curcumin?

With that in mind, the results are even more exciting to see; Longvida’s free curcumin outperformed the unformulated 80% free curcumin in all tested parameters. Longvida showed greater permeability than 80% in vitro, decreased reactive oxygen species (ROS) production, and prevented apoptic death.²

“These new studies from Dr.’s Maiti and Dunbar show that the Longvida® formulation retains excellent neuroprotective and amyloid binding activities in vitro. The superior bioavailability and sensitivity of Longvida® in detecting amyloid deposits in brain are consistent with the promising in vivo human clinical trial retinal amyloid imaging results reported by Neurovision and AIBL trial investigators at international meetings,” Dr. Gregory Cole, Interim Director, Mary S Easton Alzheimer Center, Assoc Dir Research GRECC CLA VA, Prof, Depts Neurol and Med, UCLA

Expanding upon some of these results more in-depth, the researchers stated, “We also monitored the permeability of SLCP™ (Longvida®) in N2a cells [as 7-day hippocampal neurons] from 0h to 24h and observed that maximum permeability was reached within [the] first hour of SLCP administration and intensity becomes stable up to 24h [after administration],²” which further backs the results of the Swinburne study published in 2015³. Cox KH et al also indicated that 400mg of Longvida® once daily showed, “one hour after administration [Longvida®] significantly improved performance on sustained attention and working memory tasks, compared with placebo.”³ Both Maiti and Cox et al support Longvida with statistically significant results for cognitive health.

Next, researchers examined cell death and cell survival markers after exposure to Aβ42. They indicated that, “with Aβ42-treatment, whereas SLCP™, but not Curcumin, was able to decrease these protein levels.”² Longvida® was also shown to mediate p-tau after exposure to Aβ42; as they showed that without Longvida, Aβ42 exposure significantly increased (p>0.01) p-tau.²

“Not only is it very exciting to see these results from Maiti P et al, but it is absolutely fantastic to have additional support for our previous research efforts on Longvida,” states Kristen Marshall, Marketing Coordinator, Verdure Sciences. “This new publication brings the full picture into perspective and helps to answer a lot of questions that were previously posed. Yet, the most exciting part is to see a comparative of Longvida’s free curcumin to unformulated free curcumin. We are finally able to see an equal comparison – a picture that was previously unavailable.”

Combined together, these studies show that Longvida’s efficacious free curcumin is delivered in a single daily dose to offer tangible health benefits. The key to the success of Longvida lies within the patented and proprietary Solid Lipid Curcumin Particle Technology, or SLCP™. This technology encapsulates the free curcumin in Longvida® in a tri-lipid matrix, allowing it to survive digestion and enter the bloodstream, target tissues, and cross the blood brain barrier. Furthermore, Gota VS et al says that oral administration of Longvida® (SLCP) in capsule form to healthy humans at a dose of 650mg showed appreciable plasma concentrations, compared to none detected for the 95% curcuminoids extract.⁴ They then go on to show Longvida to have a 7.5hr half-life and support the 24hr delivery of efficacious levels of Longvida® into the bloodstream and target tissues.

Researchers were able to provide statistically significant support in favor of the patented technology. They showed a greater deterrence of Aβ42-induced neuronal aptosis with SLCP™; with greater deterrence than unformulated free curcumin at lower doses. They go on to say that, “we speculate that more [free] curcumin was delivered by [Longvida®] SLCP™ than by [unformulated free curcumin].”²

They then summarize saying that, “because of its greater permeability or stability, [Longvida®] conferred more neuroprotection than [unformulated curcumin].² †

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Quatrefolic®, the metabolically active form of folate, has just earned approval as Food Additive in South Korea by the Ministry of Food and Drug Safety (MFDS) with the official addition to the Food Additive Code.

The new regulatory status allows Quatrefolic® to be used in health functional foods with the permitted claims:
– Necessary for maintenance of normal blood homocysteine levels;
– Necessary for proper growth of a fetal neural tube;
– Necessary for the production of cells and blood.

The great success follows the already obtained various authorizations in several countries all over the world, confirming the relevant role that Quatrefolic® is gaining in the prevention and management of folate deficiencies, with the proven benefits of being structurally analog to the physiological L-methylfolate, and being used by the body without metabolization for direct utilization in the folate cycle.

The Food Additive Approval follows the very recent Seminar dedicated to Quatrefolic® and organized by Gnosis in Seoul, held by the Commercial Director Paolo Malesani with the aim of informing healthcare professionals, doctors and scientist about the evolution of this “innovActive” folate.
Quatrefolic® is the metabolic active form of folate so it completely bypasses the “damaged” MTHFR conversion step and delivers a “finished” folate the body can immediately use without any kind of metabolization, avoiding the accumulation of UnMetabolized Folic Acid (UMFA) in the blood, potentially dangerous for health.